Healthcare Services Group Earnings Call Transcripts
Fiscal Year 2026
-
Q1 saw 3.4% revenue growth, strong margins, and robust cash flow, driven by new client wins and operational excellence. Guidance targets mid-single-digit growth for 2026, with disciplined cost and capital management, and continued focus on organic and inorganic growth.
Fiscal Year 2025
-
Q4 capped a strong year with revenue up 6.6% and net income of $31.2 million, driven by disciplined execution and robust industry demand. 2026 guidance calls for mid-single-digit revenue growth, continued margin discipline, and a $75 million share repurchase plan.
-
Q3 saw robust revenue, earnings, and cash flow growth, driven by new client wins and high retention. Segment margins remained solid, with significant ERC-related benefits and active share repurchases. The outlook remains positive, with strong fundamentals and a focus on organic and M&A-driven growth.
-
Q2 2025 saw 7.6% revenue growth and strong client retention, offset by a $61.2M non-cash charge from Genesis Healthcare's bankruptcy. Guidance for mid-single-digit growth and higher cash flow was reiterated, with accelerated $50M share buybacks planned.
-
Q1 delivered the strongest revenue and cash flow in five years, with 5.7% revenue growth and improved collections. Guidance for 2025 cash flow from operations was raised, and a tuck-in acquisition plus share repurchases support growth.
Fiscal Year 2024
-
Q4 2024 saw strong revenue, net income, and cash flow, with growth driven by healthcare and dining segments. 2025 guidance calls for mid-single-digit revenue growth, stable margins, and robust cash flow, supported by favorable industry trends and disciplined capital allocation.
-
Q3 saw sequential and year-over-year growth in revenue, earnings, and cash flow, with strong collections and positive industry trends. Management reaffirmed 2024 guidance and remains optimistic for 2025, supported by robust demand and effective cost management.
-
Q2 revenue met expectations at $426.3M, with a net loss of $1.8M due to restructuring charges. Cash collections improved, and 2024 cash flow guidance of $40–$55M was reaffirmed, with H2 expected to recover delayed collections. Industry trends and reimbursement remain favorable.